Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025
Authors:
- Christine SimmonsCSChristine Simmons
- Omar F. KhanOKOmar F. Khan
- Christine Brezden-MasleyCBChristine Brezden-Masley
- David W. CesconDCDavid W. Cescon
- Anil Abraham JoyAJAnil Abraham Joy
- Nathalie LeVasseurNLNathalie LeVasseur
- Katarzyna J. JerzakKJKatarzyna J. Jerzak
- Karen A. GelmonKaren A. Gelmon
- Sandeep SehdevSandeep Sehdev
- Stephen ChiaStephen Chia
- Marc WebsterMWMarc Webster
- Scott EdwardsSEScott Edwards
Open Access
- 24 April 2026
- journal article
- consensus statement
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 243
Abstract
Triple-negative breast cancer (TNBC) has been associated with a poorer prognosis than other subtypes, due to its more aggressive behaviour. Since 2020, significant advances in locoregional and systemic therapy have improved outcomes for patients with TNBC, but the implementation of these treatments remains inconsistent across Canada. There is, therefore, a critical need for evidence-informed, consensus-driven guidance to support the integration of new therapies into practice. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a pan-Canadian group of breast cancer specialists and Breast Cancer Canada, a patient advocacy organization, convened to develop national clinical consensus recommendations for the management of breast cancer. Through a selective literature review and modified Delphi process of national experts in the fields of medical oncology, radiation oncology, surgical oncology and pharmacy, REAL Alliance developed national consensus recommendations for the management of TNBC. The result is a set of 23 recommendations: four overall general recommendations, 11 in early-stage TNBC, and eight in metastatic TNBC. These recommendations are intended for oncology healthcare professionals, and are intended to guide evidence-informed, consistent care across Canada.Keywords
Funding Information
- Breast Cancer Canada (#10)
This publication has 138 references indexed in Scilit:
- Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor TherapyJAMA Network Open, 2025
- Early Integrated Palliative Care in Patients With Advanced CancerJAMA Network Open, 2024
- Survival Benefit Associated With Participation in Clinical Trials of Anticancer DrugsJAMA, 2024
- Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast CancerJAMA Oncology, 2024
- Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain MetastasesJAMA Oncology, 2023
- Platinum-containing regimens for triple-negative metastatic breast cancerCochrane Database of Systematic Reviews, 2020
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast CancerJAMA Oncology, 2020
- Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerJAMA Oncology, 2019
- Time to Surgery and Breast Cancer Survival in the United StatesJAMA Oncology, 2016
- Pelvic computed tomography of breast carcinoma patientsCancer, 1997